Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells

1,2:5,6-Dianhydrogalactitol (DAG) is a bi-functional DNA-targeting agent currently in phase II clinical trial for treatment of temozolomide-resistant glioblastoma (GBM). In the present study, we investigated the cytotoxic activity of DAG alone or in combination with common chemotherapy agents in GBM...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Beibei, Li, Yue, Kotapalli, Sudha Sravanti, Bacha, Jeffrey, Brown, Dennis, Steinø, Anne, Daugaard, Mads
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381652/
https://www.ncbi.nlm.nih.gov/pubmed/32709853
http://dx.doi.org/10.1038/s41419-020-02780-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381652/
https://www.ncbi.nlm.nih.gov/pubmed/32709853
http://dx.doi.org/10.1038/s41419-020-02780-8

Ejemplares similares